Idiopathic Pulmonary Fibrosis (IPF): Seven-Market Drug Forecast and Market Analysis

List of Tables

This report covers the 7 major markets and provides an Excel-based forecast model for the Idiopathic Pulmonary Fibrosis (IPF) market through 2034.

GlobalData estimated that drug sales for IPF in 2024 were approximately $2.7 billion across the 7MM, with the market size anticipated to grow to approximately $5.8 billion by 2034, at a compound annual growth rate (CAGR) of 7.7%.

Major drivers of growth during the forecast period include the launches of several pipeline agents, most notably Jascayd (nerandomilast), Tyvaso (treprostinil), and admilparant, the increase in the number of diagnosed prevalent cases of IPF throughout the 7MM, the increase in the use of combination therapy and the number of patients on disease-modifying therapies.

Scope

Overview of Idiopathic Pulmonary Fibrosis (IPF), including epidemiology, symptoms, diagnosis, and disease management.
Annualized IPFtherapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the IPF therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for IPF treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global IPF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM IPF therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM IPF therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC329PIDR-7M

List of Tables

List of Figures

1 Idiopathic Pulmonary Fibrosis: Executive Summary

1.1 IPF market to increase slightly from 2024-34
1.2 Innovative small pharma companies require partnerships to successfully commercialize clinical pipeline
1.3 High unmet clinical needs remain for more effective drugs with cleaner safety profiles
1.4 Late-stage pipeline span across different mechanisms of action
1.5 What do physicians think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology
- 3.1.1 Genetic factors
- 3.1.2 Environmental factors
- 3.1.3 Pathophysiology
3.2 Classification or staging systems
- 3.2.1 GAP model
- 3.2.2 Stratification by decline in FVC

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 7MM forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of IPF
4.5 Epidemiological forecast for IPF (2024-34)
- 4.5.1 Diagnosed prevalent cases of IPF
- 4.5.2 Age-specific diagnosed prevalent cases of IPF
- 4.5.3 Sex-specific diagnosed prevalent cases of IPF
4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 Limitations of the analysis
- 4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

6 Current Treatment Options

6.1 Overview
6.2 Symptomatic treatments

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Therapies that reverse progression
7.3 Improved drug safety, tolerability, and side effects
7.4 Treatments for patients with severe disease

8 R&D Strategies

8.1 Overview
- 8.1.1 Regulatory designations
- 8.1.2 Sponsor activity
- 8.1.3 Combination therapy
- 8.1.4 Clinical trials design
- 8.1.5 Increased use of quality-of-life measures

9 Pipeline Assessment

9.1 Overview
9.2 Innovative drugs in clinical development
9.3 In-class improvement and symptomatic treatment

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive assessment

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends
- 11.2.1 Partnerships, licensing agreements and mergers and acquisitions in IPF

12 Market Outlook

12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
- 13.3.1 Forecasting Methodology
13.4 Primary Research - KOLs and Payers Interviewed for This Report
- 13.4.1 KOLs
13.5 Primary Research - Prescriber Survey
13.6 About the Authors
- 13.6.1 Analyst
- 13.6.2 Associate Director
- 13.6.3 Therapy Area Director
- 13.6.4 Epidemiologist
- 13.6.5 Managing Epidemiologists
- 13.6.6 Vice President of Disease Analysis and Intelligence
- 13.6.7 Global Head of Pharma Research, Analysis, and Competitive Intelligence
About GlobalData
Contact Us

Product Code: GDHC329PIDR-7M

List of Table

List of Tables

Table 1: IPF: Key metrics in the 7MM
Table 2: The GAP index
Table 3: Risk factors and comorbidities for IPF
Table 4: Overview of IPF treatment guidelines
Table 5: Leading treatments for IPF, 2025
Table 6: Most commonly prescribed symptomatic treatments for IPF
Table 7: Top 10 deals by value, 2023-25
Table 8: IPF market - global drivers and barriers, 2024-34
Table 9: Key events impacting sales for IPF in the US, 2024-34
Table 10: IPF market - drivers and barriers in the US, 2024-34
Table 11: Key events impacting sales for IPF in the 5EU, 2024-34
Table 12: IPF market - drivers and barriers in the 5EU, 2024-34
Table 13: Key events impacting sales for IPF in Japan, 2024-34
Table 14: IPF market - drivers and barriers in Japan, 2024-34
Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figure

List of Figures

Figure 1: Global sales forecast by country for IPF in 2024 and 2034
Figure 2: Competitive assessment of the marketed and pipeline systemic drugs benchmarked against the SOCs, Esbriet and Ofev
Figure 3: The induction and progression of IPF
Figure 4: 7MM, diagnosed prevalence of IPF (%), both sexes, ages >=18 years, 2024
Figure 5: 7MM, sources used and not used to forecast the diagnosed prevalent cases of IPF
Figure 6: 7MM, diagnosed prevalent cases of IPF, N, both sexes, ages >=18 years, 2024
Figure 7: 7MM, diagnosed prevalent cases of IPF by age, N, both sexes, 2024
Figure 8: 7MM, diagnosed prevalent cases of IPF by sex, N, ages >=18 years, 2024
Figure 9: Flowchart of the diagnosis and management of IPF
Figure 10: Unmet needs and opportunities in IPF
Figure 11: Overview of the development pipeline in IPF
Figure 12: Key late-stage trials for promising agents that GlobalData expects to be licensed for IPF in the 7MM during the forecast period
Figure 13: Competitive assessment of marketed and pipeline systemic drugs benchmarked against the SOC, Ofev and Esbriet
Figure 14: Analysis of the company portfolio gap in IPF during the forecast period, 2024-34
Figure 15: Global (7MM) sales forecast by country for IPF in 2024 and 2034
Figure 16: Global (7MM) sales forecast by drug for IPF in 2024 and 2034
Figure 17: Sales forecast by class for IPF in the US in 2024 and 2034
Figure 18: Sales forecast by class for IPF in the 5EU in 2024 and 2034
Figure 19: Sales forecast by class for IPF in Japan in 2024 and 2034

Idiopathic Pulmonary Fibrosis (IPF): Seven-Market Drug Forecast and Market Analysis

Description

Table of Contents

List of Tables

Scope

Reasons to Buy

Table of Contents

Table of Contents

List of Tables

List of Figures

1 Idiopathic Pulmonary Fibrosis: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Current Treatment Options

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

12 Market Outlook

13 Appendix

List of Table

List of Tables

List of Figure

List of Figures